Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: A population-based analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: A population-based analysis

Published:2014-03-27 Issue:2 Volume:110 Page:163-170
ISSN:0022-4790
Container-title:Journal of Surgical Oncology
language:en
Short-container-title:J. Surg. Oncol

Author:

Amini Neda¹²,Ejaz Aslam¹,Spolverato Gaya¹,Kim Yuhree¹,Herman Joseph M.³,Pawlik Timothy M.¹

Affiliation:

1. Department of Surgery; Johns Hopkins Hospital; Baltimore Maryland

2. Cancer Research Center; Cancer Institute of Iran; Tehran University of Medical Sciences; Tehran Iran

3. Department of Radiation Oncology; Johns Hopkins Hospital; Baltimore Maryland

Publisher

Wiley

Subject

Oncology,General Medicine,Surgery

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jso.23605/fullpdf

Reference50 articles.

1. Bektas H Schrem H Kleine M 2013 91 116

2. Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis;Chang;J Natl Compr Cancer Netw,2009

3. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe;Bertuccio;Ann Oncol,2013

4. Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma;Reddy;J Gastrointest Surg,2013

5. Cholangiocarcinoma;Khan;Lancet,2005

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research progress and prospect of postoperative adjuvant therapy for resectable intrahepatic cholangiocarcinoma;Frontiers in Pharmacology;2024-08-07

2. Neoadjuvant therapy reduces node positivity but does not confer survival benefit versus up‐front resection for resectable intrahepatic cholangiocarcinoma: A propensity‐matched analysis;Journal of Surgical Oncology;2024-07-31

3. Case report: Translational treatment of unresectable intrahepatic cholangiocarcinoma: Tislelizumab, Lenvatinib, and GEMOX in one case;Frontiers in Oncology;2024-07-15

4. Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations;Cancer Research and Treatment;2024-07-15

5. Management of intrahepatic and perihilar cholangiocarcinomas: Guidelines of the French Association for the Study of the Liver (AFEF);Liver International;2024-07-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3